Sensei Biotherapeutics Acquires Faeth, Issues 10.5M Share‑Equivalent Preferred Stock and Secures $200M PIPE

*TL;DR Sensei Biotherapeutics closed a merger with Faeth Therapeutics, issued 10.5 million share‑equivalent Series B preferred shares to Faeth owners and raised $200 million by selling 14.44 million additional preferred shares at $13.85 per common‑share equivalent.*

Context Sensei Biotherapeutics (NASDAQ: SNSE) announced the acquisition of Faeth Holdings Therapeutics and its subsidiary on February 17, 2026. The deal expands Sensei’s pipeline in oncology and immunology, adding Faeth’s pre‑clinical assets to a market‑cap of roughly $1.2 billion.

Key Facts - Under the merger agreement, Sensei issued 10,497.098 Series B non‑voting convertible preferred shares to Faeth shareholders. Each preferred share converts into 1,000 common shares, yielding an as‑converted total of 10,497,098 common shares. - Simultaneously, Sensei entered a securities purchase agreement to sell 14,440.395 Series B preferred shares to new and returning investors. The price of $13,850 per preferred share translates to $13.85 per common‑share equivalent, generating $200 million in gross proceeds. - The financing closed on February 20, 2026, three days after the merger announcement. Conversion of all Series B preferred shares into common stock is set to occur automatically three business days after shareholder approval of the parent‑stockholder matters, scheduled for June 10, 2026. - Post‑conversion, the combined entity will have approximately 24.94 million additional common shares, diluting existing shareholders but providing a cash infusion equal to roughly 16.7 % of the pre‑deal market cap.

What It Means The merger gives Sensei immediate access to Faeth’s therapeutic candidates, potentially accelerating its entry into late‑stage trials. The $200 million PIPE (private‑placement financing) strengthens the balance sheet, extending the cash runway into 2028 and reducing reliance on future equity offerings. However, the conversion will increase share count, pressuring earnings per share unless the new assets generate revenue quickly.

Investors will watch the June 10 shareholder vote for approval of the parent‑stockholder matters, as the outcome determines the timing of the conversion and the final dilution impact. Subsequent quarterly reports will reveal how the cash infusion is allocated to R&D and whether the combined pipeline narrows the gap to profitability.

*Next watch*: Sensei’s Q3 earnings release and any regulatory updates on Faeth’s lead candidates.